erythromycin ethylsuccinate + sulfisoxazole acetyl

**Erythromycin ethylsuccinate + sulfisoxazole acetyl** is a combination oral antibiotic suspension formulated for pediatric use. It is indicated primarily for the treatment of **acute otitis media in children caused by susceptible strains of Haemophilus influenzae**[4][5][7][9][10][11][12]. The combination contains a macrolide (erythromycin, as ethylsuccinate) and a short-acting sulfonamide (sulfisoxazole, as acetyl ester): - **Erythromycin** inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, leading to suppression of protein synthesis in susceptible organisms and is generally bacteriostatic[1][2][7]. - **Sulfisoxazole** is a bacteriostatic sulfonamide that competitively inhibits dihydrofolic acid synthetase, interfering with the utilization of p-aminobenzoic acid (PABA) and thus inhibiting folic acid synthesis, which is essential for bacterial growth[7]. The combination exhibits synergistic effects, **lowering the minimal inhibitory concentrations (MIC)** of each drug when used together and increasing efficacy against H. influenzae[7]. Commonly administered orally as a reconstituted suspension, especially in children.

Brand names

Pediazole

Other names

erythromycin and sulfisoxazole